Newton, PA-based Bio-Imaging Technologies has purchased a segment of Quintiles Transnational that specializes in providing digital medical imaging services for clinical trials and the healthcare industry. Financial terms were not disclosed. The services
Newton, PA-based Bio-Imaging Technologies has purchased a segment of Quintiles Transnational that specializes in providing digital medical imaging services for clinical trials and the healthcare industry. Financial terms were not disclosed. The services provided by this business unit, called Intelligent Imaging, include image data management, data translation, and digitization for submission of medical image data to the FDA and clinical sponsors, using proprietary interactive software. The unit supports a wide variety of medical information, x-rays, MR, CT, nuclear medicine, PET, and ultrasound scans. Bio-Imaging Technologies specializes in helping clients design and manage the medical imaging component of clinical trials.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.